Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 3 Interventional Results available

Efficacy and Safety of Semaglutide Once-weekly Versus Exenatide ER 2.0 mg Once-weekly as add-on to 1-2 Oral Antidiabetic Drugs (OADs) in Subjects With Type 2 Diabetes

ClinicalTrials.gov ID: NCT01885208

Public ClinicalTrials.gov record NCT01885208. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Sep 2, 2026, 2:16 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

Efficacy and Safety of Semaglutide Once-weekly Versus Exenatide ER 2.0 mg Once-weekly as add-on to 1-2 Oral Antidiabetic Drugs (OADs) in Subjects With Type 2 Diabetes (SUSTAIN™ 3 - vs. QW GLP-1)

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

This trial is conducted in Europe and North and South America. The aim of the trial is to investigate the efficacy and safety of semaglutide once-weekly versus exenatide ER (extended release) 2.0 mg once-weekly as add-on to 1-2 oral antidiabetic drugs (OADs) in subjects with type 2 diabetes.

Study identification

NCT ID
NCT01885208
Recruitment status
Completed
Study type
Interventional
Phase
Phase 3
Lead sponsor
Novo Nordisk A/S
Industry
Enrollment
813 participants

Conditions and interventions

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Dec 1, 2013
Primary completion
Jul 12, 2015
Completion
Jul 12, 2015
Last update posted
Jun 12, 2019

2013 – 2015

United States locations

U.S. sites
76
U.S. states
24
U.S. cities
64
Facility City State ZIP Site status
Novo Nordisk Investigational Site Anniston Alabama 36207
Novo Nordisk Investigational Site Birmingham Alabama 35216
Novo Nordisk Investigational Site Pell City Alabama 35128
Novo Nordisk Investigational Site Glendale Arizona 85306-4652
Novo Nordisk Investigational Site Mesa Arizona 85213
Novo Nordisk Investigational Site Phoenix Arizona 85027
Novo Nordisk Investigational Site Burbank California 91505
Novo Nordisk Investigational Site Hawaiian Gardens California 90716
Novo Nordisk Investigational Site Lomita California 90717
Novo Nordisk Investigational Site Los Angeles California 90017
Novo Nordisk Investigational Site Los Angeles California 90022
Novo Nordisk Investigational Site Los Angeles California 90057
Novo Nordisk Investigational Site Northridge California 91324
Novo Nordisk Investigational Site Northridge California 91325
Novo Nordisk Investigational Site San Diego California 92108
Novo Nordisk Investigational Site Tustin California 92780
Novo Nordisk Investigational Site Colorado Springs Colorado 80906
Novo Nordisk Investigational Site Colorado Springs Colorado 80909
Novo Nordisk Investigational Site Bradenton Florida 34201
Novo Nordisk Investigational Site Brandon Florida 33511
Novo Nordisk Investigational Site Coral Gables Florida 33134
Novo Nordisk Investigational Site Hialeah Florida 33012
Novo Nordisk Investigational Site Jacksonville Florida 32207
Novo Nordisk Investigational Site Miami Florida 33144
Novo Nordisk Investigational Site Miami Florida 33145
Novo Nordisk Investigational Site Miami Florida 33174
Novo Nordisk Investigational Site Miami Lakes Florida 33016
Novo Nordisk Investigational Site Plantation Florida 33324
Novo Nordisk Investigational Site Savannah Georgia 31406
Novo Nordisk Investigational Site Chicago Illinois 60634
Novo Nordisk Investigational Site Franklin Indiana 46131
Novo Nordisk Investigational Site Greenfield Indiana 46140
Novo Nordisk Investigational Site Muncie Indiana 47304
Novo Nordisk Investigational Site Louisville Kentucky 40213
Novo Nordisk Investigational Site Madisonville Kentucky 42431
Novo Nordisk Investigational Site Hyattsville Maryland 20782
Novo Nordisk Investigational Site Kalamazoo Michigan 49009
Novo Nordisk Investigational Site St Louis Missouri 63141
Novo Nordisk Investigational Site Las Vegas Nevada 89103
Novo Nordisk Investigational Site Mine Hill New Jersey 07803
Novo Nordisk Investigational Site Albuquerque New Mexico 87102
Novo Nordisk Investigational Site North Massapequa New York 11758-1802
Novo Nordisk Investigational Site Syracuse New York 13210
Novo Nordisk Investigational Site West Seneca New York 14224
Novo Nordisk Investigational Site Greensboro North Carolina 27408
Novo Nordisk Investigational Site Hickory North Carolina 28601
Novo Nordisk Investigational Site Whiteville North Carolina 28472
Novo Nordisk Investigational Site Akron Ohio 44311
Novo Nordisk Investigational Site Cincinnati Ohio 45255
Novo Nordisk Investigational Site Cleveland Ohio 44122
Novo Nordisk Investigational Site Delaware Ohio 43015
Novo Nordisk Investigational Site Corvallis Oregon 97330-3737
Novo Nordisk Investigational Site Portland Oregon 97210
Novo Nordisk Investigational Site Portland Oregon 97239
Novo Nordisk Investigational Site Lansdale Pennsylvania 19446-1002
Novo Nordisk Investigational Site Norristown Pennsylvania 19401
Novo Nordisk Investigational Site Charleston South Carolina 29407
Novo Nordisk Investigational Site Mt. Pleasant South Carolina 29464
Novo Nordisk Investigational Site Murrells Inlet South Carolina 29576
Novo Nordisk Investigational Site Spartanburg South Carolina 29303
Novo Nordisk Investigational Site Chattanooga Tennessee 37404
Novo Nordisk Investigational Site Austin Texas 78731
Novo Nordisk Investigational Site Carrollton Texas 75010
Novo Nordisk Investigational Site Dallas Texas 75225
Novo Nordisk Investigational Site Dallas Texas 75390-8858
Novo Nordisk Investigational Site Fort Worth Texas 76117
Novo Nordisk Investigational Site Houston Texas 77008
Novo Nordisk Investigational Site Houston Texas 77024
Novo Nordisk Investigational Site Houston Texas 77040
Novo Nordisk Investigational Site Houston Texas 77072
Novo Nordisk Investigational Site Irving Texas 75039
Novo Nordisk Investigational Site Katy Texas 77450
Novo Nordisk Investigational Site San Antonio Texas 78245
Novo Nordisk Investigational Site Sugar Land Texas 77478
Novo Nordisk Investigational Site Sugar Land Texas 77479
Novo Nordisk Investigational Site Alexandria Virginia 22304

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 70 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT01885208, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Jun 12, 2019 · Synced Sep 2, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT01885208 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →